Myriad Genetics, Inc.’s MYGN MyRisk Hereditary Cancer Test with RiskScore study has been named as one of its top 10 significant advances in genomic medicine by the American Journal of Human Genetics....
Through 2024, advancements in AI and predictive analytics rapidly revolutionized the Medical Instruments industry, driving innovation in diagnostics, patient monitoring and personalized treatment. AI-powered...
Teleflex TFX recently launched its new Pressure Injectable Arrowg+ard Blue Plus MSB Procedure Kit in Europe, the Middle East and Africa (EMEA). This is regarded as a significant addition to the company’s...
Myriad Genetics, Inc.’s MYGN Prolaris prostate cancer prognostic test has been reinforced as an ‘Advanced Tool’ by the National Comprehensive Cancer Network (“NCCN”) in the fight against prostate...
Charles River Laboratories International, Inc. CRL has launched the Charles River Incubator Program (“CIP”) via its Global Innovation Center of Excellence (CoE). The initiative is designed to support...
Johanna Roberts, the EVP of $PEN ($PEN), sold 281 shares of the company on 12-02-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.4% of their shares. Following...
Adam Elsesser, the CEO and President of $PEN ($PEN), sold 3,281 shares of the company on 11-20-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.4% of their...
Investors in Penumbra, Inc. PEN need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 20, 2024 $310 Put had some of the highest implied volatility...
The latest news from the lab, plus an analyst's bullish move, combined to put some zip in the company's shares.